Drugs /
h3b-6527
Back to Drugs List
Overview
NCI Definition [1]:
An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis.
Clinical Trials
H3b-6527 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating h3b-6527, 1 is phase 1 (1 open).
Hepatocellular carcinoma is the most common disease being investigated in h3b-6527 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
